An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes
Author:
Affiliation:
1. Corcept Therapeutics Menlo Park California USA
2. Jade Consultants (Cambridge) Ltd Cottenham Cambridge UK
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1731
Reference18 articles.
1. Identification of the clinical candidate (R)‐(1‐(4‐fluorophenyl)‐6‐((1‐methyl‐1H‐pyrazol‐4‐yl)sulfonyl)‐4,4a,5,6,7,8‐hexahydro‐1H‐pyrazolo[3,4‐g]isoquinolin‐4a‐yl)(4‐(trifluoromethyl)pyridin‐2‐yl)methanone (CORT125134): a selective glucocorticoid receptor (GR) antagonist;Hunt HJ;J Med Chem,2017
2. Incidence and late prognosis of Cushing's syndrome: a population‐based study;Lindholme J;Clin Endocrinol Metab,2001
3. Epidemiology of Cushing’s Syndrome
4. Korlym®(mifepristone) [prescribing information]. Menlo Park CA: Corcept Therapeutics;2019.
5. Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study;The Oncologist;2024-08-26
2. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer;Clinical Cancer Research;2024-03-27
3. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer;Journal of Gynecologic Oncology;2024
4. Relacorilant, un nuovo bloccante selettivo del recettore dei glucocorticoidi;L'Endocrinologo;2023-09-18
5. Research Methods and New Advances in Drug–Drug Interactions Mediated by Renal Transporters;Molecules;2023-07-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3